Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Halozyme Therapeutics has a consensus analyst rating of “Moderate Buy”, with 7 buy ratings, 4 hold ratings, and 1 sell rating among 12 analysts. The average 12-month price target is about $80.67.
• The company recently beat earnings and revenue estimates, reporting EPS of $1.60 versus $1.54 expected and revenue of $376.71 million versus $358.60 million expected. Revenue also jumped 42.2% year over year.
• Despite positive analyst sentiment, there has been notable insider selling, including sales by the COO and a director, while institutional ownership remains high at 97.79%. Analysts also recently raised or reiterated bullish price targets, including Benchmark at $90 and HC Wainwright at $95.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) has been given an average recommendation of "Moderate Buy" by the twelve analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $80.6667.

A number of equities analysts recently commented on the company. Wells Fargo & Company lifted their price objective on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Thursday, February 19th. TD Cowen reiterated a "buy" rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Weiss Ratings upgraded Halozyme Therapeutics from a "hold (c)" rating to a "buy (b-)" rating in a research report on Tuesday, May 12th. Benchmark lifted their price objective on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a "buy" rating in a research report on Thursday, February 19th. Finally, HC Wainwright lifted their price objective on Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a "buy" rating in a research report on Wednesday, April 29th.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $68.65 on Thursday. The company has a market cap of $8.14 billion, a PE ratio of 24.69, a price-to-earnings-growth ratio of 0.28 and a beta of 0.89. The stock's 50 day simple moving average is $66.03 and its 200-day simple moving average is $68.77. Halozyme Therapeutics has a 1-year low of $51.06 and a 1-year high of $82.22. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.06. The business had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The business's quarterly revenue was up 42.2% compared to the same quarter last year. During the same quarter last year, the business posted $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, equities research analysts anticipate that Halozyme Therapeutics will post 7.65 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, COO Cortney Caudill sold 8,857 shares of Halozyme Therapeutics stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $67.64, for a total value of $599,087.48. Following the completion of the sale, the chief operating officer directly owned 7,055 shares of the company's stock, valued at approximately $477,200.20. The trade was a 55.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Bernadette Connaughton sold 1,625 shares of the business's stock in a transaction on Friday, May 1st. The stock was sold at an average price of $63.48, for a total value of $103,155.00. Following the transaction, the director directly owned 38,498 shares of the company's stock, valued at $2,443,853.04. The trade was a 4.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 120,482 shares of company stock valued at $8,200,842 over the last quarter. 2.50% of the stock is owned by insiders.

Institutional Trading of Halozyme Therapeutics

Institutional investors have recently bought and sold shares of the business. Empowered Funds LLC acquired a new position in Halozyme Therapeutics in the 1st quarter valued at about $755,000. Acadian Asset Management LLC acquired a new position in Halozyme Therapeutics in the 1st quarter valued at about $195,000. Hsbc Holdings PLC increased its position in Halozyme Therapeutics by 117.1% in the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company's stock valued at $522,000 after acquiring an additional 5,448 shares during the period. EverSource Wealth Advisors LLC increased its position in Halozyme Therapeutics by 6.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company's stock valued at $140,000 after acquiring an additional 174 shares during the period. Finally, Baird Financial Group Inc. increased its position in Halozyme Therapeutics by 6.2% in the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company's stock valued at $577,000 after acquiring an additional 650 shares during the period. 97.79% of the stock is owned by hedge funds and other institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.